NOTE PAYABLE (Details Textual) - USD ($)		1 Months Ended		12 Months Ended
	Mar. 03, 2017	Feb. 24, 2017	Sep. 28, 2016	Sep. 30, 2018	Sep. 30, 2017	Feb. 20, 2017	Sep. 30, 2013
Note Payable [Line Items]
Debt Instrument, Payment Terms				The loan originally bore interest at a rate of 10% per annum, and was originally scheduled to become fully due and payable on the earlier of (i) September 30, 2018, (ii) the occurrence of an event of default under the MLSC Loan Agreement, or (iii) the completion of a sale of substantially all of our assets, a change-of-control transaction (“Qualified Sale”) or one or more financing transactions in which we receive from third parties other than our then existing shareholders net proceeds of $5,000,000 or more in a 12-month period
Debt instrument, unamortized discount					$ 0
Repayments of Notes Payable				$ 0	1,000,000
REGISTERED DIRECT OFFERING 2017 [Member]
Note Payable [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.75
Stock Issued During Period, Value, New Issues		$ 6,100,000
Loans
Note Payable [Line Items]
Notes Payable				944,707
2014 Warrant
Note Payable [Line Items]
Notes Payable				55,293
Interest Expense, Debt				0	$ 22,100
Massachusetts Life Sciences Center
Note Payable [Line Items]
Subordinated Debt				$ 1,000,000			$ 1,000,000
Debt Instrument, Payment Terms			(i) interest on the MLSC Loan decreased from 10% per annum to 7% per annum beginning October 3, 2016; and (ii) the MLSC Loan became due and payable on the earlier of October 3, 2017 (“Maturity Date”), the occurrence of a Corporate Event (which was defined as the occurrence of either a Qualified Sale or Qualified Financing), or the occurrence of a Default (as defined in the promissory note issued in connection with the MLSC Loan Agreement). In addition, under the terms of the Amendment, (a) beginning October 3, 2016, the Company began amortizing the principal and accrued interest under the MLSC Loan by making the first of 13 monthly payments of approximately $106,022, with the last payment scheduled to occur on the Maturity Date; and (b) the term “Qualified Financing” was defined to mean one or more financing transactions in which we receive, in a single transaction or series of transactions, cumulative net proceeds of not less than five million dollars ($5,000,000) at any time after October 3, 2016.
Warrants Issued To Purchase Of Common Stock							145,985
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.27
Debt Instrument, Increase, Accrued Interest			$ 232,000
Debt Instrument, Interest Rate, Stated Percentage			7.00%
Repayments of Notes Payable	$ 830,000
Debt Instrument, Reduction In Interest Expenses	$ 250,000